A New Turning Point in Menopausal Hormone Therapy: The FDA's 10 November 2025 Revision

On 10 November 2025, the US Food and Drug Administration (FDA) announced that, for hormone replacement therapies (HRT/MHT) used to treat menopausal symptoms, the longstanding boxed warnings (black box) would enter a process for removal . The move aims to reframe broad interpretations from the early 2000s about cardiovascular disease, breast cancer, and possible dementia risks in light of updated evidence. It generated widespread public, media, and clinical discussion. 

 The Decision in Brief: What Was Announced?

• The FDA announced that it had begun the process for more than 20 systemic and some local estrogen/progestogen products used for menopausal symptoms, removing the general boxed warning and working with manufacturers on label updates . Labels will be rewritten to emphasize individualized risk assessment. 
• Exception: For patients with a uterus receiving estrogen alone (without progestin), warnings about endometrial hyperplasia/cancer remain, highlighting this established clinical concern. 
• Rationale: Accumulated evidence suggests that the 2002 WHI findings were interpreted too broadly, without distinguishing age groups , potentially overstating risks for women under 60 or newly menopausal. 

 Why Was This Revision Needed?

Published in the early 2000s, Women’s Health Initiative (WHI) data showed signals of increased cardiovascular events and breast cancer risk, particularly in older postmenopausal women receiving combined estrogen+progestin therapy. Over time, variables such as age at initiation and time since menopause onset were found to substantially influence the risk–benefit balance: For women under 60 and/or within the first 10 years of menopause , an overall risk increase cannot be generalized; benefits such as symptom control, bone health, and improved metabolic parameters may be more prominent. 

The FDA's assessment drew on a literature review, a summer expert panel, and public consultation. It aims to strengthen individualized decision-making in place of generalized fear .

 What Changes? (Labeling and Clinical Practice)

• Boxed warning language will be removed, replacing an absolute, broadly discouraging perception with emphasis on risk stratification and shared decision-making .
• Local vaginal estrogen and similar formulations with low systemic absorption will have their low-risk profiles, reported for years, communicated more clearly. 
• For patients with a uterus receiving systemic estrogen, the need for added progestin and warnings about endometrial risk remain. 

What Does This Mean for Patients?

The FDA's 10 November 2025 decision marks an important change for women using or considering menopausal hormone therapy. It aims to move beyond the generalized fear that “hormone therapy is dangerous” toward balanced, individualized decisions based on each woman's health, age, and risk profile.

The decision does not mean hormone therapy is entirely risk-free; however, it acknowledges that previous boxed warnings (black box) unnecessarily discouraged many patients from treatment. The message is: Hormone therapy may be safe for the right patient, at the right dose, and at the right time.

Particularly in women under 60 or less than 10 years since menopause , benefits (for hot flashes, sleep, vaginal dryness, bone health, and quality of life) may outweigh risks. Each woman is different, however; cardiovascular disease, hypertension, clotting disorders, breast cancer history, or excess weight may change the decision.

The FDA announcement also emphasized once again that local vaginal hormone products carry much lower risks. Because little enters the bloodstream, systemic side-effect risk is minimal, making them an effective, safe option particularly for vaginal dryness, painful intercourse, or recurrent urinary tract infections.

In Türkiye: FDA decisions do not apply directly but generally influence international guidelines. Similar updates from the European Menopause and Andropause Society (EMAS) and local women's health organizations are therefore expected soon.

Hormone therapy is moving beyond an “all-or-nothing” approach to become a personalized, careful, monitored medical option . It must always be undertaken with regular medical follow-up, with periodic review of dose and duration.

 What Does This Mean for Healthcare Professionals?

The FDA's 10 November 2025 HRT labeling revision officially recognizes that evidence accumulated after WHI “cannot be generalized to all women” , placing individualized risk stratificationat the center of clinical practice. The aim is to strengthen shared decision-making rather than fear-based communication.

1) For Whom, When, and at What Dose/Form?

• In symptomatic women under 60 and/or within the first 10 years of menopause , low-dose systemic (particularly transdermal) or combined therapies often have an acceptable risk profile.
• In patients with a uterus , systemic estrogen is not given without progestin. (Alternative: endometrial protection with an LNG-IUD.)
• After hysterectomy , estrogen monotherapy may be considered.
• Genitourinary syndrome (vaginal dryness, dyspareunia, recurrent UTIs) as the main problem favors local vaginal estrogen ; systemic absorption is minimal.

2) Before Starting and During Follow-Up

• Initial assessment: Cardiovascular risk (ASCVD), VTE history, BP, lipid profile, BMI, DM; breast screening (age-appropriate mammography), if a uterus is present , endometrial assessment as indicated.
• Drug selection and dose: “Lowest effective dose & shortest duration”; the transdermal route may offer VTE and TG advantages in some patients.
• Follow-up: Reassess symptoms, dose, side effects, and goals every 6–12 months; taper the dose or discontinue treatment if needed.

3) Multidisciplinary Collaboration

• Cardiology/Internal Medicine: ASCVD scoring, HTN/DM management, statin/anticoagulant interactions.
• Gynecology/Oncology: Individualized breast and endometrial risks, planned screening intervals.
• Pharmacy: Label updates, formulation–generic equivalence, drug interactions (CYP inducers/inhibitors), and patient counseling.

4) Communication and Documentation

• Shared decision-making: Explain symptom goals, nonhormonal alternatives, expected benefits, and possible risks in patient-friendly language.
• Informed consent & records: Clearly document the rationale, dose/formulation, follow-up plan, and “reassessment date.”

 Criticism and Open Questions

• Some experts criticized the FDA for not fully using the traditional advisory committee model during the process, raising transparency concerns. 
• Although label wording is being softened, risks have not disappeared; unsuitable patient selection may have serious consequences. Clinical decisions must always be individualized. 

The FDA's 10 November 2025 announcement may accelerate the shift from fear-centered communication to evidence-based, personalized menopause care. It does not mean HRT is suitable for every woman; rather, with the right patient, timing, and formulation, it enables accessible, balanced consideration of treatment. Clinical practice should put information before fear.

References

1. FDA News Release — HHS Advances Women’s Health, Removes Misleading FDA Warnings on HRT (10 Nov 2025). 
2. HHS Press — Removes Misleading FDA Warnings on HRT (10 Nov 2025). 
3. AP News — The FDA removes a long-standing warning from hormone-based menopause drugs (10 Nov 2025). 
4. Reuters — FDA to lift black box warnings from menopause hormone therapies (10 Nov 2025)
5. Washington Post — FDA to lift warnings on menopause hormone therapy (10 Nov 2025)
6. STAT News — FDA reverses hormone warning (10–11 Nov 2025). 
7. Scientific American — FDA Strips Health Risk Warnings from Menopause Hormone Therapy (11 Nov 2025). 
8. FDA Direct Podcast — Removing Black Box Warnings for HRT (1/2–2/2) (10 Nov 2025).
9. TIME — FDA Removes Black Box Warning on Hormone Therapy